Introduction
Antioxidant defense mechanisms are required to prevent cellular damage observed in various diseases. Impairment of the antioxidants and antioxidant systems could be related to increased oxidative stress.
1,2 Therefore, drugs possessing antioxidant and free radical scavenging properties are considered for preventing and/or treatment of diseases that are directly involved with the lack of antioxidant capacity of organisms. It is known that lipid peroxidation (LP) is a free radical-initiated reaction that causes the degeneration of the cell membranes 3 and is involved in the evaluation of the antioxidant properties of a compound. Most products of lipid peroxidation are known to have mutagenic and/or carcinogenic properties. Furthermore, reactive oxygen/nitrogen species are produced by different mechanisms such as cytochrome P450 (CYP)-dependent enzymes that metabolize chemicals and endogenous substances. In this system, CYP1A1/2 have an important role in NADPHdependent LP. Therefore, it is important to evaluate the effects of synthesized compounds on NADPH-dependent LP and CYP systems. 4 On the other hand, DPPH assay is recommended as an accurate method for measuring the antioxidant capacity of various compounds.
5
Previously, we have reported the synthesis, characterization, and antioxidant properties of some benzimidazole derivatives containing thiadiazole, triazole, oxadiazole, and thiazolidinone rings at the first position.
6−14
In the present study, the design and synthesis of some novel benzimidazole derivatives having an oxadiazole ring * Correspondence: sgurkan@pharmacy.ankara.edu.tr 
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Cl - (5) (6) (7) (8) (9) (10) (11) (12) and arylmethyleneamino acetamide (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (Table 1) were performed and their antioxidant properties were investigated (Table 2) .
Results and discussion
Chemistry
The desired benzimidazole derivatives were synthesized according to the Scheme. Firstly, 2-(4-chlorophenyl)- 
In vitro antioxidant activity
The synthesized compounds were evaluated based on their antioxidant effects on the rat liver microsomal NADPH-dependent lipid peroxidation (LP) levels by measuring the formation of 2-thiobarbituric acid reactive substances (TBARS) ( Table 2 ). The in vitro inhibitory effect of intermediate thiol compound 4b bearing benzyloxyphenyl at the second position of the benzimidazole ring on LP levels was stronger (78%) than that of the corresponding S -substituted 1,3,4-oxadiazole derivatives. On the other hand, compound 4a bearing chloro substituent showed no activity on LP levels. 10 5-Mercapto-S -substituted 1,3,4-oxadiazole derivatives (5) (6) (7) (8) (9) (10) (11) (12) had moderate inhibitory activity on LP levels in the range of 46%-61%, whereas imine containing compounds (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) exhibited diverse levels of activity. Compounds 15 (68%) and 18 (100%) displayed the highest activity among all of the synthesized compounds. The most active compound, 18, led to 100% inhibition on LP level, while butylated hydroxy toluene (BHT) showed 65% inhibition at the same concentration.
The compounds were tested for their in vitro effects on liver microsomal EROD activity. The inhibitory effects of intermediate thiol compound 4b on EROD activity were more powerful (97%) than those of the corresponding 5-mercapto-S -substituted 1,3,4-oxadiazole derivatives 10-12, while compound 4a displayed the lowest inhibitory activity (40%) on EROD 10 among all of the compounds. All the final 1,3,4-oxadiazole derivatives caused significant inhibition (77%-95%) of EROD activity. Typically, imine-containing compounds (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) showed better EROD inhibitory effects than 1,3,4-oxadiazoles (5-12). All the compounds except 7
(79%), 10 (77%), and 12 (77%) inhibited microsomal EROD activity better than (87%-97%) standard caffeine (85%), while compounds 6 and 13 possessed the same inhibitory effect as caffeine (85%) ( Table 2 ).
The compounds' interaction with the stable free radical DPPH was also examined. It was observed that the final compounds did not show a significant inhibition in the DPPH scavenging assay, except compound (85%). Furthermore, the DPPH radical scavenger capacities of the intermediate thiol compounds 4a and 4b were the same (88%) at 10 −3 M concentration ( These findings indicate that some of the synthesized compounds possess beneficial effects on the human antioxidant defense system and have been suggested to act as antioxidants. Therefore, they could be thought as promising treatment candidate compounds for diseases related to excess of some reactive species.
Conclusion
The synthesized compounds had different effects on the systems examined. Compound 18, which bears 2-pyridinyl, showed the best inhibitory activity on liver microsomal LP levels (100%) and EROD (92%). Intermediate thiol compound 4b and final imine compounds 17 and 19, bearing 4-pyridinyl and 5-nitrofuran-2-yl substituents, respectively, had the most powerful inhibitory effect (97%) on EROD. Among all of the final compounds, compound 12 displayed the highest inhibition (76%) in the DPPH scavenging assay. The substitution of intermediate 4b with benzylic groups led to a reduction in the antioxidant activity for all systems tested, while the substitution of intermediate 4a decreased the DPPH scavenging activity at the same concentration.
Experimental section
General synthesis
All starting materials and chemical reagents used in the synthesis were high-grade commercial products purchased from Aldrich or Merck (Germany). BHT and caffeine were obtained from Sigma. Analytical thin-layer chromatography was performed with Merck precoated TLC plates, and spots were visualized with ultraviolet light. Column chromatography was accomplished on silica gel 60 (40-63-µ m particle size) (Merck, Germany). Melting points were determined with an Electrothermal 9100 digital melting point apparatus and were uncorrected. The structures of all synthesized compounds were assigned on the basis of NMR and mass spectral analyses.
1 H NMR and 
5-((2-(4-(Benzyloxy)phenyl)-1H -benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazole-2-thiol (4b)
General procedure for the preparation of 2-(substitutedbenzylthio)-5-((2-(4-chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazoles (5-9) and 2-(substitutedbenzylthio)-5-((2-(4-(benzyloxy)phenyl)-1H -benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazoles (10-12)
To a mixture of the thiol compound 4a (or 4b) (0.15 mmol) in 0.1 mL of 1 N KOH and 1 mL of H 2 O was added corresponding benzylbromide (0.15 mmol). The mixture was stirred overnight at room temperature. The end of the reaction was monitored by TLC. The solid separated was collected and dried. The crude product was purified by column chromatography eluting with an appropriate solvent system or by recrystallization from ethanol to give 5-12.
2-(Benzylthio)-5-((2-(4-chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazole (5)
Crude 5 was purified by column chromatography (n-hexane/ethyl acetate 
2-(4-Bromobenzylthio)-5-((2-(4-chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-1,3,4-oxadiazole (6)
Crude 6 was recrystallized from ethanol to provide 6 (yield 44%) as a white solid, mp 159 
2-((2-(4-Chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-5-(2,4-dichlorobenzylthio)-1,3,4-oxadiazole (7)
Crude 7 was recrystallized from ethanol to provide 7 (yield 45%) as a white solid, mp 166-168 
2-((2-(4-Chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-5-(4-fluorobenzylthio)-1,3,4-oxadiazole (8)
2-((2-(4-Chlorophenyl)-1H -benzo[d]imidazol-1-yl)methyl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole (9)
Crude 9 was recrystallized from ethanol to provide 9 (yield 40%) as a white solid, mp 154-155 
2-((2-(4-(Benzyloxy)phenyl)-1H -benzo[d]imidazol-1-yl)methyl)-5-(4-bromobenzylthio)-1,3,4-oxadiazole (10)
Crude 10 
2-((2-(4-(Benzyloxy)phenyl)-1H -benzo[d]imidazol-1-yl)methyl)-5-(2,4-dichlorobenzylthio)-1,3,4-oxadiazole (11)
Crude 11 was purified by column chromatography (n-hexane/ethyl acetate (2:1)) to provide 11 (yield 36% 
2-(2-(4-Chlorophenyl)-1H -benzo[d]imidazol-1-yl)-N ′ -((3-methylthiophen-2-yl) methylene) acetohydrazide (14)
White All tests and analyses were run in triplicate and averaged. The standard used in this assay was BHT. 
7-Ethoxyresorufin O-deethylase (EROD) assay
7-Ethoxyresorufin O-deethylase (EROD) enzyme activity was determined by the spectrofluorometric method described by Burke et al. 20 A typical optimized assay mixture contained 1.0 mM ethoxyresorufin; 10 −3 M test compound; 100 mM Tris-HCl buffer pH 7.8; a NADPH-generating system consisting of 0.25 mM NADP + , 2.5 mM MgCl 2 , 2.5 mM glucose-6-phosphate, 1.0 U glucose-6-phosphate dehydrogenase, and 14.2 mM potassium phosphate buffer pH 7.8; and 0.2 mg of liver microsomal protein in a final volume of 1.0 mL. The standard used in this assay was caffeine. DMSO was used as a control.
Lipid peroxidation (LP) assay
Male albino Wistar rats (200-225 g) were used in the experiments. The animals were fed with standard laboratory rat chow and tap water ad libitum. The animals were starved for 24 h prior to sacrifice and were killed by decapitation under anesthesia. The livers were removed immediately and washed in ice-cold water, and the microsomes were prepared as defined previously. 21 NADPH-dependent LP was determined using the optimum conditions as determined and described previously 21 and measured spectrophotometrically by estimation of thiobarbituric acid-reactive substances (TBARS). Amounts of TBARS were expressed in terms of nmol malondialdehyde (MDA)/mg protein. The assay was essentially obtained from the methods of Wills 22, 23 as modified by Bishayee et al. 24 LP was measured spectrophotometrically at 532 nm as the thiobarbituric acid-reactive material. Compounds inhibit the production of MDA, and the color produced after addition of thiobarbituric acid is less intensive. A typical optimized assay mixture contained 10 −3 M test compound; 0.2 nM Fe ++ ; 90 mM KCl; 62.5 mM potassium phosphate buffer, pH 7.4; a NADPH-generating system comprising 0.25 mM NADP + , 2.5 mM MgCl 2 , 2.5 mM glucose-6-phosphate, 1.0 U glucose-6-phosphate dehydrogenase, and 14.2 mM potassium phosphate buffer pH 7.8; and 0.2 mg of microsomal protein in a final volume of 1.0 mL. The standard used in this assay was BHT. DMSO was used as a control.
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